Tumor-on-a-chip platforms to study cancer–immune system crosstalk in the era of immunotherapy

descriptionPublicationkeyboard_double_arrow_right Article 01 Jan 2021 Italy English Publisher:Royal Society of Chemistry (RSC)Journal:Lab on a Chip, volume 21, pages 234-253 (issn: 1473-0197, eissn: 1473-0189,

Copyright policy )Funded by:EC | INVICTUS

Authors: Parlato S.; Grisanti G.; Sinibaldi G.; Peruzzi G.; Casciola C. M.; Gabriele L.;

doi: 10.1039/d0lc00799d

pmid: 33315027

handle: 11573/1493808

Tumor-on-a-chip platforms to study cancer–immune system crosstalk in the era of immunotherapy

- Summary
- Subjects
- Metrics

Abstract

Immunotherapy is a powerful therapeutic approach able to re-educate the immune system to fight cancer. In this scenario, tumor-on-chip can help to choose the right immunotherapeutic treatment.

Country

Italy

Related Organizations

Istituto Superiore di Sanità
Italy
Roma Tre University
Italy
Sapienza University of Rome
Italy
Center for Life Sciences
China (People's Republic of)
Italian Institute of Technology
Italy

Keywords

microfluidics; immunotherapy; tumor-on-a-chip, Immune System, Lab-On-A-Chip Devices, Neoplasms, Tumor Microenvironment, Humans, Immunotherapy

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	50
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%